Union européenne - français - EMA (European Medicines Agency)

viatris limited - bésilate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agents antithrombotiques - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Élévation du segment st infarctus aigu du myocarde, en association avec de l'aas dans traitée médicalement les patients éligibles à un traitement thrombolytique. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pour de plus amples informations, veuillez vous reporter à la section 5.

Union européenne - français - EMA (European Medicines Agency)

viatris limited - la pirfénidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosuppresseurs - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Union européenne - français - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - les médicaments utilisés dans le diabète - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 et 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - périndopril arginine 2,5 mg - eq. périndopril 1,698 mg - comprimé pelliculé - 2,5 mg - périndopril arginine 2.5 mg - perindopril

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - périndopril arginine 2,5 mg - eq. périndopril 1,698 mg - comprimé pelliculé - perindopril

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - atorvastatine calcique 10,844 mg - eq. atorvastatine 10 mg; macrogol 0,631 - comprimé pelliculé - 10 mg - atorvastatine calcique 10.84 mg - atorvastatin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - atorvastatine calcique trihydraté 21,688 mg - eq. atorvastatine 20 mg - comprimé pelliculé - 20 mg - atorvastatine calcique 21.69 mg - atorvastatin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - atorvastatine calcique trihydraté 43,376 mg - eq. atorvastatine 40 mg - comprimé pelliculé - 40 mg - atorvastatine calcique 43.38 mg - atorvastatin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - atorvastatine calcique trihydraté 86,751 mg - eq. atorvastatine 80 mg - comprimé pelliculé - 80 mg - atorvastatine calcique 86.75 mg - atorvastatin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - atorvastatine calcique trihydraté 21,688 mg - eq. atorvastatine 20 mg - comprimé pelliculé - 20 mg - atorvastatine calcique 20.72 mg - atorvastatin